SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained or incorporated by reference in this prospectus, any accompanying prospectus supplement and any related free writing prospectus constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. In some cases, you can identify forward-looking statements by the words “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” and or the negative of these terms, or other comparable terminology intended to identify statements about the future. From time to time, we publish forward-looking statements relating to matters such as anticipated financial performance, business prospects, technological developments, new products, research and development activities and other aspects of our present and future business operations as well as similar matters.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. While it is impossible to identify or predict all such matters, these differences may result from, among other things:
•
our ability to commercialize KORSUVA injection including the timing of additional regulatory submissions and approvals, and execute on our marketing plans for any other drugs or indications that may be approved in the future;
•
our ability to obtain and maintain coverage and adequate reimbursement for KORSUVA injection;
•
the performance of our current and future collaborators and licensees, including VFMCRP, Vifor, Maruishi, and CKDP, as well as sub-licensees, including Kissei, and our ability to maintain such collaborations;
•
risks that KORSUVA injection revenue, expenses and costs may not be as expected;
•
the performance of third-party manufacturers and clinical research organizations, or CROs;
•
risks relating to KORSUVA injection’s market acceptance, competition, reimbursement and regulatory actions;
•
the size and growth of the potential markets for pruritus management, including CKD-aP, in hemodialysis and non-dialysis markets, chronic liver disease associated pruritus, or CLD-aP, pruritus associated with atopic dermatitis, or AD-aP, and pruritus associated with NP markets;
•
the success and timing of our clinical trials and reporting of our results from these trials, including our clinical trial programs for Oral KORSUVA (difelikefalin) in CKD-aP, CLD-aP, AD-aP, and NP;
•
our plans to develop and commercialize Oral KORSUVA (difelikefalin) and any future product candidates;
•
the potential results of ongoing and planned preclinical studies and clinical trials and future regulatory and development milestones for our product candidates;
•
the rate and degree of market acceptance of any other future approved products;
•
our ability to obtain and maintain additional regulatory approval of our product candidates, and the labeling under any approval we may obtain;
•
the anticipated use of Enteris Biopharma, Inc.’s, or Enteris’s, Peptelligence® technology to develop, manufacture and commercialize Oral KORSUVA (difelikefalin);
•
our ability to establish additional collaborations for our product candidates;